Adi Mohanty is Co-CEO and President of BioTime. He joined the company in 2014. He is a Director of BioTime, as well as a Director of affiliate companies, Asterias Biotherapeutics and OncoCyte. Mr. Mohanty brings a diverse set of skills with more than 20 years of experience in biotech and biopharma. He was formerly with Shire plc, a biotech company focused on research, development and commercialization of novel biological products for rare diseases, where he served in a number of executive positions including President/Head of Regenerative Medicine and as Global Franchise Head MPS. Mr. Mohanty was VP of Manufacturing and Operations at Transkaryotic Therapies (TKT) when it was acquired by Shire in 2005. Before joining TKT, he held a number of management positions in the Bioscience Division of Baxter Healthcare Corporation. Mr. Mohanty has an MBA as well as MS and BS in Chemical Engineering. Mr. Mohanty has a passion for growing businesses, products and people and has been involved in several successful product approvals and launches and businesses that went from zero to multi-billion dollar annual revenues.

Back